Clinical research
Good safety profile and encouraging efficacy reported for recurrent glioblastoma patients with disrupted blood-brain barrier
The American Association for Cancer Research (AACR) Annual Meeting is taking place in Atlanta. Here’s a look at just a few stories coming out of the meeting.
Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant
NOXXON Pharma N.V. announced the latest update of clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the American Association for Cancer Research Annual Meeting.
MD Anderson Phase II trial shows drug well tolerated with high response rates for marginal zone lymphoma
Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC)
The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.
Bone marrow transplants are both incredibly risky as well as expensive procedures. Nonetheless, they are still effective and have been used by doctors since the 1950s, with many successful procedures completed over the years.
The American Association for Cancer Research (AACR) Annual Meeting is ongoing in Atlanta, with plenty of companies presenting interesting and cutting-edge science. Here’s a look at just a representative few.
The late-stage studies funded by the financing round could set the stage for two potential regulatory approvals if the data remains strong.
PRESS RELEASES